QuantumPharm, Inc. (2228) AI Stock Analysis

• Market Cap: $22.89B
• Dividend Yield: N/A
• Average Volume (3M): 83.31M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: 50.10%
• EPS Growth: -212.76%
• Country: HK
• Employees: 809
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -1.93
• Shares Outstanding: 4,017,001,700
• 10 Day Avg. Volume: 79,821,486
• 30 Day Avg. Volume: 83,311,962
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: 168.57
• Enterprise Value/Gross Profit: 366.90
• Enterprise Value/Ebitda: -44.51
• 1Y Price Target: $6.00
• Price Target Upside: -3.07% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 56 Neutral
• Price Target: $6.50 ▲(5.01% Upside)

QuantumPharm, Inc. shows strong technical indicators, supporting near-term momentum. However, significant financial performance issues, including profitability challenges and negative cash flows, weigh heavily on its overall stock score. Valuation concerns further impact the score, given the negative P/E ratio and lack of a dividend.

Positive Factors

Revenue Growth

XtalPi leverages its proprietary AI-powered R&D platform to deliver stable and accelerating revenue growth across two core business areas: drug discovery and intelligent robotics.

Strategic Partnerships

XtalPi collaborates with leading global and domestic pharma companies, enhancing its strategic position in drug discovery.

Negative Factors

R&D Risks

Risks include potential delays in partnered R&D pipelines, uncertainty in commercialization sustainability, and possible sell-off following lock-up expiry.

QuantumPharm, Inc. Business Overview & Revenue Model

Company Description

QuantumPharm, Inc. (2228) is a leading biotechnology company specializing in the development and commercialization of innovative pharmaceutical solutions. The company focuses on leveraging quantum computing and advanced molecular modeling to accelerate drug discovery and development processes. QuantumPharm's core products include a pipeline of proprietary therapeutics targeting rare and complex diseases, as well as offering strategic partnerships for technology licensing and collaborative research initiatives.

How the Company Makes Money

QuantumPharm, Inc. generates revenue primarily through the commercialization of its proprietary pharmaceutical products. Key revenue streams include the sale of approved therapeutics, licensing agreements for its advanced drug discovery technologies, and partnerships with pharmaceutical companies for collaborative research and development. Additionally, the company may receive milestone payments and royalties from licensed products developed using its technology platforms. Strategic alliances with research institutions and biotech firms further contribute to its earnings by expanding its technological reach and market presence.

QuantumPharm, Inc. Financial Statement Overview

Summary

QuantumPharm, Inc. shows strong revenue growth, but persistent losses and negative cash flows are concerning. Improvements in debt and equity offer some stability, but profitability and cash flow issues remain critical challenges.

Income Statement

QuantumPharm, Inc. has shown significant revenue growth from 2019 to 2024, yet the company struggles with profitability. Gross Profit Margin improved to 46.31% in 2024 from 27.66% in 2023, but the company continues to incur substantial net losses, with a Net Profit Margin of -569.33% in 2024. The negative EBIT and EBITDA margins highlight ongoing operational challenges.

Balance Sheet

The company has made notable improvements in its balance sheet, reducing total debt significantly from 2023 to 2024. The Debt-to-Equity Ratio has improved due to a positive equity position in 2024. However, the Equity Ratio remains a concern, reflecting potential financial instability.

Cash Flow

Operating Cash Flow has improved slightly, yet remains negative, impacting the company's ability to generate positive Free Cash Flow. Despite the improvement in financing activities, the Free Cash Flow to Net Income Ratio remains unfavorable, indicating ongoing cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2019
Income Statement
Total Revenue	266.43M	174.42M	133.35M	62.80M	0.00
Gross Profit	123.43M	48.24M	66.09M	32.78M	0.00
EBITDA	-631.38M	-1.78B	-390.37M	-2.11B	-9.84M
Net Income	-1.52B	-1.91B	-1.44B	-2.14B	-36.03M
Balance Sheet
Total Assets	4.35B	4.01B	4.32B	4.38B	8.44M
Cash, Cash Equivalents and Short-Term Investments	3.10B	2.83B	3.47B	3.83B	8.44M
Total Debt	148.76M	11.04B	9.45B	7.83B	159.05M
Total Liabilities	362.43M	11.25B	9.63B	7.99B	219.45M
Stockholders Equity	3.96B	-7.27B	-5.33B	-3.61B	-211.01M
Cash Flow
Free Cash Flow	-536.79M	-698.20M	-627.83M	-417.42M	655.00K
Operating Cash Flow	-478.68M	-567.56M	-429.10M	-253.75M	655.00K
Investing Cash Flow	74.09M	735.58M	-2.76B	-70.47M	33.00K
Financing Cash Flow	840.00M	-25.89M	57.99M	2.48B	0.00

QuantumPharm, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.19
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2228, the sentiment is Positive. The current price of 6.19 is above the 20-day moving average (MA) of 5.98, above the 50-day MA of 5.63, and above the 200-day MA of 5.78, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 63.73 is Neutral, neither overbought nor oversold. The STOCH value of 54.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2228.

QuantumPharm, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2268	67 Neutral	HK$70.95B	60.87	17.75%	―	―	―
2502	61 Neutral		7.33	-1.60%	4.22%	30.77%	-128.09%
Sector *	59 Neutral	HK$15.62B	28.59	-16.88%	4.75%	8.45%	-109.32%
2228	56 Neutral	$22.89B	―		―	50.10%	-212.76%
2509	55 Neutral		―		―	―	―
2498	41 Neutral	HK$15.35B	―	-12.70%	―	―	―
2511	36 Underperform	HK$1.90B	―	-67.57%	―	―	54.79%

QuantumPharm, Inc. Corporate Events

XtalPi and DoveTree Enter Definitive Agreement for AI-Driven Drug Discovery

XtalPi Holdings Limited, through its subsidiary Shenzhen XtalPi Technology Co., Ltd., has entered into a definitive agreement with DoveTree Medicines LLC to leverage its AI drug discovery platform for developing small molecule and antibody drug candidates. This collaboration focuses on oncology, immunologic and inflammatory diseases, neurological disorders, and metabolic dysregulation, with DoveTree obtaining exclusive development and commercialization rights. The agreement includes an initial payment of $51 million to XtalPi, with potential further payments and royalties based on product sales.

The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

XtalPi Partners with DoveTree for AI-Driven Drug Discovery

XtalPi Holdings Limited has entered into a term sheet with DoveTree LLC to collaborate on drug discovery using its AI and robotics platform. This partnership will focus on developing small molecule and antibody drug candidates for tumors, autoimmune, and neurological diseases, potentially leading to significant financial gains and global commercialization rights for DoveTree.

The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

XtalPi Co-Founders Extend Lock-Up, Signaling Confidence

XtalPi Holdings Limited, a company incorporated in the Cayman Islands, has announced that its co-founders have voluntarily extended their lock-up undertakings for another year, demonstrating their confidence in the company’s long-term value and future prospects. This extension involves a total of 591,488,405 shares, representing 14.71% of the issued share capital, and is seen as a positive signal for stakeholders, potentially stabilizing the company’s stock and reinforcing its market position.

The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

XtalPi Holdings Acquires 90% Stake in Target Company for RMB250 Million

XtalPi Holdings Limited, a company incorporated in the Cayman Islands, has announced a significant acquisition involving a 90% equity interest in a target company for RMB250 million, to be fully settled in cash. This transaction is considered a discloseable transaction under the Listing Rules, as it exceeds the 5% threshold but is below 25%, thus requiring reporting and announcement. The acquisition will result in the target company becoming an indirect non-wholly owned subsidiary of XtalPi, potentially enhancing its market position and operational capabilities.